Keyword: Conatus Pharmaceuticals

Non-alcoholic fatty liver disease

3. Emricasan

Conatus’ pan-caspase inhibitor emricasan is one of a pair of drugs for NASH that made it onto our list for 2019, and its failure cost the company a partnership with Novartis that was providing all its revenue and forced it to lay off 40% of its workforce.
Fail sign

2019’s top 15 clinical trial flops (and a flip-flop)

This year’s top 15 list has been drawn up to include trials whose failure we judge to have had material consequences on their sponsors and the patients for whom the drugs are being developed. The catalog includes multiple trials for aggressive brain cancer, Alzheimer’s disease, nonalcoholic steatohepatitis and heart disease.